Bioxyne Ltd
BXN
Company Profile
Business description
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments namely, wholesale sales, Plant-based, Manufacturing sales, and direct sales. The majority of the revenue is generated from plants based segment.
Contact
50 Clarence Street
Suite 506, Level 5
SydneyNSW2000
AUST: +61 290787669
Sector
Consumer Defensive
Stock type
Defensive
Industry
Packaged Foods
Fiscal Year End
30 June 2025
Employees
16
Stocks News & Analysis
stocks
The 10 best US dividend stocks
These undervalued stocks with reliable dividends are worth considering.
stocks
Australian stocks will crush housing over the next decade, one year on
James Gruber looks back on his forecast for Australian equities and the housing market
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,577.80 | 21.60 | -0.25% |
| CAC 40 | 7,453.65 | 1.23 | 0.02% |
| DAX 40 | 20,287.26 | 42.68 | -0.21% |
| Dow JONES (US) | 42,635.20 | 106.84 | 0.25% |
| FTSE 100 | 8,302.29 | 51.26 | 0.62% |
| HKSE | 19,240.89 | 38.95 | -0.20% |
| NASDAQ | 19,478.88 | 10.80 | -0.06% |
| Nikkei 225 | 39,605.09 | 375.97 | -0.94% |
| NZX 50 Index | 12,943.74 | 99.37 | -0.76% |
| S&P 500 | 5,918.25 | 9.22 | 0.16% |
| S&P/ASX 200 | 8,329.20 | 19.90 | -0.24% |
| SSE Composite Index | 3,211.39 | 18.77 | -0.58% |